Login to Your Account



Zytiga prostate win may be just the start as test proceeds into development

By Randy Osborne
Staff Writer

Monday, June 5, 2017

CHICAGO – For men with prostate cancer (PC), the already good news regarding Zytiga (abiraterone, Johnson & Johnson) that came out of the American Society of Clinical Oncology (ASCO) meeting may get even better, and soon.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription